Dendreon Corporation  

(Public, NASDAQ:DNDN)   Watch this stock  
Find more results for DNDN
2.65
-0.04 (-1.49%)
Real-time:   12:07PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.64 - 2.73
52 week 2.23 - 5.38
Open 2.69
Vol / Avg. 757,631.00/2.87M
Mkt cap 421.28M
P/E     -
Div/yield     -
EPS -1.95
Shares 158.98M
Beta 5.70
Inst. own 40%
May 5, 2014
Q1 2014 Dendreon Corporation Earnings Release (Estimated) Add to calendar
Apr 21, 2014
Dendreon Corporation Annual Shareholder Meeting (Estimated) Add to calendar
Mar 4, 2014
Dendreon Corporation at Cowen Health Care Conference
Mar 3, 2014
Q4 2013 Dendreon Corporation Earnings Release
Mar 3, 2014
Q4 2013 Dendreon Corporation Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -118.58% -104.60%
Operating margin -100.64% -85.65%
EBITD margin - -54.78%
Return on average assets -74.42% -51.37%
Return on average equity - -
Employees 755 -
CDP Score - -

Address

SUITE 3200, 1301 2ND AVE.
SEATTLE, WA 98101
United States - Map
+1-206-2197815 (Phone)
+1-206-2560571 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may significantly improve cancer treatment options for patients. The Company's product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating multiple types of cancers. PROVENGE (sipuleucel-T), is the Company's first commercialized product approved by the United States Food and Drug Administration (FDA), and is a autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. The Company owns worldwide rights for PROVENGE. Other product candidates the Company has under development include its investigational active cellular immunotherapy, DN24-02. The Company completed its Phase I clinical trial in April 2012 to evaluate Transient Receptor Potential, sub-family M (TRPM8).

Officers and directors

John H. Johnson Chairman of the Board, President, Chief Executive Officer
Bio & Compensation  - Reuters
Gregory R. Cox Interim Chief Financial Officer, Principal Accounting Officer
Age: 47
Bio & Compensation  - Reuters
Gregory T. Mayes III Executive Vice President - Human Resources
Age: 44
Bio & Compensation  - Reuters
William Monteith Executive Vice President - Technical Operations
Age: 55
Bio & Compensation  - Reuters
Lindsay Rocco Executive Vice President - Corporate Communications
Age: 34
Bio & Compensation  - Reuters
Andrew S. Sandler M.D. Executive Vice President, Chief Medical Officer
Bio & Compensation  - Reuters
Robert Crotty Interim General Counsel, Interim Secretary
Bio & Compensation  - Reuters
Douglas G. Watson Lead Independent Director
Age: 68
Bio & Compensation  - Reuters
David L. Urdal Ph.D. Director
Age: 63
Bio & Compensation  - Reuters
Susan B. Bayh Independent Director
Age: 53
Bio & Compensation  - Reuters